leisure time -WSS

leisure time

author：hotspot 2025-09-30 08:52:15 - browse：312

A cloud with a medical folder on the top of an illustration is connected to other medical vectors such as a doctor on a phone screen, a health watch, and a brain chip — coverage from STAT — Adobe

Federal health technology regulators on Wednesday finalized new rules to force software vendors to disclose how artificial intelligence tools are trained, developed, and tested — a move to protect patients against biased and harmful decisions about their care.

The rules are aimed at placing guardrails around a new generation of AI models gaining rapid adoption in hospitals and clinics around the country. These tools are meant to help predict health risks and emergent medical problems, but little is publicly known about their effectiveness, reliability, or fairness.

Starting in 2025, electronic health record vendors who develop or supply these tools, which increasingly use a type of AI known as machine learning, will be required to disclose more technical information to clinical users about their performance and testing, as well as the steps taken to manage potential risks.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： How Long Island became the ‘eugenics capital of the world’

hotspot

WSS

CDC advisory panel says seniors 'may' get RSV vaccine

Appeals court upholds limits to abortion pill

Why more medical students aren't specializing in primary care

WHO may add ‘noma' to its list of neglected tropical diseases

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Radiation, mainstay of cancer treatment, begins a fade

Wikipedia

leisure time

hotspot

New air purifier tech could be key to improving indoor air quality

Diversity in medical illustrations gets boost from Chidiebere Ibe

In Memoriam: Notable people who died in 2023

Winners, losers from Medicare’s list of drugs subject to price talks

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: What happened with Sarepta's Duchenne data

Heart attack and stroke risk calculators need revising

2024 GOP presidential candidates spar over abortion in debate

entertainment

Physician subsidies by hospitals soar in wake of No Surprises Act

Emergency medicine has repudiated 'excited delirium.' Now what?

Psilocybin's anti

What do new weight loss drugs mean for bariatric surgery?

In science, is the line between industry and academia shifting?

Diversifying clinical trials isn't enough to close racial gaps: study

hotspot

hotspot

hotspot

explore